Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) October 28, 2011 -- GlobalData estimated the pneumonia therapeutics market to be worth $1,988m in 2010. It is forecast to
decline at a Compound Annual Growth Rate (CAGR) of 1.1% to reach $1,815m by 2018. The market deteriorated during 2005-2010 owing to the patent expiries of major drugs such as Zithromax (azithromycin), Zosyn (piperacillin-tazobactam) and Levaquin (levofloxacin) in 2005, 2007 and 2010 respectively. The decline during the forecast period can be attributed to the expected patent expiry of

Avelox (moxifloxacin), Tygacil (tigecycline) in 2014 and 2016 respectively. Zyvox (linezolid) will also lose its patent protection in 2015 in the US and 2016 in Europe and Japan. The late stage pipeline lacks molecules that act against antibiotic-resistant bacterial strains and is therefore unlikely to have a significant impact on the market.

Pneumonia therapeutics is broadly classified into two segments: community acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP). GlobalData’s analysis of the pneumonia therapeutics market shows low unmet need in both segments. Different classes of antibiotics such as cephalosporins,

macrolides, carbapenems, penicillins, fluoroquinolones and tetracyclines are used for the treatment of pneumonia. The pneumonia therapeutics market is well served by the approved drugs which offer significant efficacy and safety profiles. The only drawback with the current drugs is that they cannot effectively combat antibiotic resistant bacterial strains. Therefore, new entrants must understand and focus on treating the underlying cause of pathogens developing resistance to the drugs in order to gain a significant market share.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Pneumonia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&CompanyID=fprco

There is an urgent need for antibiotics that are effective in the treatment of pneumonia caused by drug

resistant bacterial strains. However, there are not enough new antibiotics in the pharmaceutical pipeline to keep pace with the need. Major pharmaceutical companies with superior research and development

(R&D) structures are losing interest in the antibiotics market, partly due to the regulatory hurdles that the companies have to face in order to obtain marketing approval. Increasingly complex clinical trials are required to gain approval with different requirements in the US and the EU. Separate development programs are required for each indication and it is difficult to conduct for specific bacterial infections even with molecular diagnostic techniques. In the case of pneumonia, the etiological agent can be viral or bacterial which poses a greater challenge to gaining approval. The guidelines are also stringent in terms of adverse events for antibiotics and there is a time lag in approval after they are filed. Owing to these factors, there are only few antibiotics that have gained approval in the last ten years. Ceftobiprole medocaril (BAL 5788) presents a classic example of the delay and regulatory hurdles in the path of approval of antibiotics. Its initial new drug application (NDA) was submitted in 2007 and is still awaiting marketing approval.

GlobalData, the industry analysis specialist, has released its new report, “Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global pneumonia therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Pneumonia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare&CompanyID=fprco

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe: +44 207 753 4299

+44 1204 543 533
Asia Pacific: +91 40 6616 6782

Pharmaceuticals and Healthcare     pneumonia     therapeutics